Logo image
Acute Hepatitis After Tetrahydroaminoacridine Administration for Alzheimerʼs Disease
Article de revue scientifique   Avec comité de lecture

Acute Hepatitis After Tetrahydroaminoacridine Administration for Alzheimerʼs Disease

Pascal Hammel, Dominique Larrey, Jacques Bernuau, Michel Kalafat, Eric Fréneaux, Gérard Babany, Claude Degott, Gérard Feldmann, Dominique Pessayre et Jean-Pierre Benhamou
Journal of clinical gastroenterology, Vol.12(3), p.329-331
06/1990
PMID: 2362104

Résumé

Tetrahydroaminoacridine administration has been proposed as a treatment for Alzheimerʼs disease. Although recent studies have shown that tetrahydroaminoacridine administration can be associated with mild or moderate liver dysfunction, to our knowledge, no case of symptomatic hepatitis with severe liver lesions has heretofore been reported. We describe a patient who developed jaundice after receiving tetrahydroaminoacridine for three weeks. Histologic examination showed extensive hepatocellular necrosis. Tetrahydroaminoacridine withdrawal was followed by the disappearance of jaundice within a few days and complete recovery within 5 weeks. This case shows that tetrahydroaminoacridine administration can induce marked liver cell necrosis resulting in symptomatic acute hepatitis.

Indicateurs

1 Consultations de la notice

Détails

Logo image